KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Current Deferred Revenue (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Current Deferred Revenue data on record, last reported at $16.0 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 7.19% year-over-year to $16.0 million; the TTM value through Sep 2025 reached $16.0 million, down 7.19%, while the annual FY2024 figure was $13.9 million, 15.16% down from the prior year.
  • Current Deferred Revenue reached $16.0 million in Q3 2025 per PACB's latest filing, up from $13.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $32.1 million in Q2 2022 and bottomed at $9.5 million in Q2 2021.
  • Average Current Deferred Revenue over 5 years is $17.4 million, with a median of $16.0 million recorded in 2025.
  • Peak YoY movement for Current Deferred Revenue: soared 236.52% in 2022, then crashed 46.42% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $11.0 million in 2021, then surged by 177.84% to $30.5 million in 2022, then plummeted by 46.42% to $16.3 million in 2023, then decreased by 15.16% to $13.9 million in 2024, then increased by 15.76% to $16.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $16.0 million in Q3 2025, $13.9 million in Q4 2024, and $17.3 million in Q3 2024.